Journal of Clinical Oncology
Articles in this Issue
ABVD versus BEACOPP for front-line treatment of Hodgkin lymphoma: A systematic review and meta-analysis.
e19039 Background: Hodgkin lymphoma is a curable malignancy, the choice of frontline therapy for advanced-stage disease re...
Artificial intelligence comparison of Google MedGemma and ChatGPT-5 in expert-reviewed gastrointestinal and genitourinary oncology cases.
e15509 Background: Large language models (LLMs) are increasingly explored for oncology decision support, yet comparative e...
Association of cardiotoxicity with chimeric antigen receptor T-cell (CAR-T) therapy: A systematic review.
e19522 Background: Chimeric antigen receptor (CAR) T-cells represent a novel and highly effective option for the treatment...
Association of post-treatment vaginal structural changes with psychosexual dysfunction in young cervical cancer survivors: Evidence from a low- and middle-income country.
5542 Background: Vaginal stenosis is a known late side effect of pelvic radiotherapy for cervical cancer. In low- and midd...
Sociodemographic and geographic disparities in early-onset pancreatic cancer mortality in the United States, 1999–2020.
e16459 Background: Early-onset pancreatic cancer (EOPC), defined as pancreatic cancer occurring before age 50,represents a...
Using large language models to assess adherence to ASCO tele-health in oncology standards in post-Covid clinical documentation.
e23238 Background: In 2021, the American Society of Clinical Oncology (ASCO) published telehealth standards and practice r...
Treatment decision-making after CAR-T and bispecific antibody therapy in relapsed/refractory multiple myeloma: Real-world perspectives from U.S. hematologist/oncologists.
e19525 Background: BCMA-directed CAR T cell therapies and bispecific antibodies (BsAbs) have transformed outcomes for pati...
Multimodal immunotherapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
6569 Background: CD117 is highly expressed on myeloid leukemia cells (MLC) with limited expression on normal tissues. Our...
Three decades of breast cancer predisposition genetic testing at a comprehensive cancer center.
e22633 Background: Uptake of germline genetic testing for breast cancer (BC) predisposition has expanded substantially ove...
Derivation and external validation of a prognostic nomogram for HER2-negative early breast cancer in young Chinese females: A population-based study.
e12728 Background: Young breast cancer (YBC) is a distinct subtype, marked by aggressive tumor biology, and worse overall...
Coverage of subcutaneous versus intravenous oncology therapies by US commercial health plans.
1554 Background: Several widely used intravenous (IV) oncology therapies have recently been reformulated for subcutaneous...
Predicting immune-related adverse events (irAEs) with large language model (LLM) embeddings.
1611 Background: irAEs are a common side effect of immune checkpoint inhibitor (ICI) therapy. Predicting irAEs from clinic...
A phase II study of trastuzumab emtansine (T-DM1) combined with ribociclib in patients with HER2-positive metastatic breast cancer (RibHER).
1041 Background: HER2-targeted therapy has significantly improved outcomes for patients with HER2-positive metastatic brea...
DCE-MRI for assessment of pathologic complete response after completion of neoadjuvant therapy in triple-negative breast cancer patients.
611 Background: Triple-negative breast cancer (TNBC) is an aggressive molecular subtype that accounts for approximately 15...
Exploring pancreatic cancer risk in rheumatoid arthritis and role of rheumatoid factor test: A retrospective cohort study using NIH All of Us database.
e16496 Background: Pancreatic cancer (PC) has rising mortality, emphasizing the need for improved risk stratification. Rhe...
Efficacy and safety of neoadjuvant disitamab vedotin (DV) in combination with toripalimab (Tor) and concurrent/sequential chemotherapy (chemo) in patients with HR-negative, HER2-low breast cancer: A randomized multicenter phase 2 study.
598 Background: For patients (pts) with triple-negative early breast cancer (BC), recommended neoadjuvant regimens include...
Risk assessment models for venous thromboembolism in patients with multiple myeloma: A systematic review and meta-analysis.
e24168 Background: Thrombosis prevention is a cornerstone of supportive care in multiple myeloma (MM), as venous thromboem...
Evaluation of a novel diagnostic kit using the semi-dry dot-blot method with an automated reader for detecting breast cancer metastases in sentinel lymph nodes: A combined analysis of two multicenter prospective studies in Japan.
586 Background: The semi-dry dot-blot (SDB) method is a diagnostic procedure for detecting lymph node (LN) metastases usin...
Clinical outcomes of enfortumab vedotin (EV) or pembrolizumab (P) interruption in metastatic urothelial carcinoma (mUC).
e16592 Background: EV–P is a standard first-line therapy for mUC. In routine practice, one agent is frequently discontinue...
Temporal evolution of prostate cancer incidence and incidence-based mortality from 2000 to 2022: A retrospective analysis by race and age at diagnosis based on USPSTF screening guidelines.
5124 Background: Prostate-specific antigen (PSA) screening guidelines have evolved substantially since 2000, influencing d...
SCALE-2: A phase 2 trial evaluating neoadjuvant short-course radiotherapy combined with chemotherapy and toripalimab in resectable locally advanced esophageal squamous cell carcinoma.
4092 Background: The SCALE-1 Phase Ib trial demonstrated that short-course neoadjuvant radiotherapy combined with toripali...
Pretreatment CT-based radiomics and machine learning models for predicting treatment response in lung cancer: A diagnostic test accuracy meta-analysis.
e20023 Background: Lung cancer remains one of the most commonly diagnosed malignancies and the leading cause of cancer-rel...
Genomic and clinical characterization of estrogen receptor–positive/HER2-negative early breast cancer: Results from the NextGIM study.
e12590 Background: Estrogen Receptor–Positive (ER+)/HER2-Negative early breast cancer (BC) is biologically heterogeneous:...
Three-month versus six-month duration of postoperative adjuvant therapy after R0 resection following conversion therapy in hepatocellular carcinoma patients achieving MPR or pCR: A prospective randomized study.
4121 Background: Conversion therapy allows a subset of patients with initially unresectable hepatocellular carcinoma (uHCC...
Tumor delivery and exposure of aldoxorubicin compared with doxorubicin: Integrated clinical and preclinical analysis.
e15134 Background: Doxorubicin is widely used across solid tumors and sarcomas but is limited by dose-dependent cardiotoxi...